Get the Stockscreener App
272.11
0.99%
2.68
After Hours:
272.11
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $272.11, with a volume of 3.09M.
It is up +0.99% in the last 24 hours and up +2.32% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$269.43
Open:
$276.97
24h Volume:
3.09M
Relative Volume:
0.99
Market Cap:
$145.97B
Revenue:
$32.53B
Net Income/Loss:
$4.23B
P/E Ratio:
34.84
EPS:
7.81
Net Cash Flow:
$6.28B
1W Performance:
+3.77%
1M Performance:
+2.32%
6M Performance:
-18.94%
1Y Performance:
-10.51%
1-Day Range:
$269.78
$276.97
1-Week Range:
$261.28
$276.97
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
272.11 | 145.97B | 32.53B | 4.23B | 6.28B | 7.81 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen: Likely To Be Rangebound (Rating Downgrade) - Seeking Alpha
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer - Yahoo Finance Australia
Amgen Inc. (AMGN): A Bull Case Theory - Insider Monkey
Annex Advisory Services LLC Has $4.11 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
FDA approves Amgen’s combo therapy for colorectal cancer - Yahoo Finance
Sax Wealth Advisors LLC Makes New $252,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Kelly Financial Services LLC Invests $3.78 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Here’s Why Amgen Inc. (AMGN) Is Among the Highest Yielding Dividend Stocks In the Dow - Insider Monkey
HB Wealth Management LLC Buys 1,768 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Cohen Klingenstein LLC Sells 1,750 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Verity & Verity LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stock Position Trimmed by Aaron Wealth Advisors LLC - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stock Position Lifted by Merit Financial Group LLC - MarketBeat
Why Amgen Inc. (AMGN) Is One of the Best Cheap Stocks to Buy for 2025? - Insider Monkey
Amgen picks up key colorectal cancer okay for KRAS drug - pharmaphorum
Why Is Amgen Inc. (AMGN) Among Louis Navellier’s Top Long-term Stock Picks? - Insider Monkey
Avanza Fonder AB Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Tompkins Financial Corp Buys 16,481 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Zoran Krunic, Senior Manager of Data Science at Amgen The Superposition Guy's Podcast: Workforce Development - The Quantum Insider
Boston Common Asset Management LLC Has $5.66 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Householder Group Estate & Retirement Specialist LLC Has $412,000 Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Empirical Asset Management LLC Purchases 3,156 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Ritholtz Wealth Management Decreases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's - Simply Wall St
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs - BioPharma Dive
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation - Benzinga
Amgen : Advancement in Combination Biomarker Driven Therapy for Adult Patients with Chemorefractory KRAS G12C Mutated Metastatic Colorectal Cancer (mCRC) - Marketscreener.com
FDA Approves Amgen’s LUMAKRAS + Vectibix for KRAS G12C-mutated Colorectal Cancer - Contract Pharma
FDA approves Amgen's Lumakras with Vectibix for mCRC - World Pharmaceutical Frontiers
FDA Approves Amgen's Groundbreaking LUMAKRAS Combination Therapy for Colorectal Cancer Treatment - StockTitan
Looking beyond obesity, Amgen wins colorectal cancer expansion for Lumakras - PharmaLive
FDA Greenlights Amgen's New Cancer Drug Combo, Boosting Survival for KRAS G12C Patients - GuruFocus.com
Occidental Asset Management LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
1,620 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Bennett Associates Wealth Management - MarketBeat
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer - Seeking Alpha
Carnegie Investment Counsel Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
JGP Wealth Management LLC Increases Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
1,041 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Tallon Kerry Patrick - MarketBeat
Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers - GlobeNewswire Inc.
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Godsey & Gibb Inc. Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
US FDA approves Amgen's colorectal cancer therapy - Reuters
Is Amgen Inc. (AMGN) Among the Best NASDAQ Dividend Stocks to Buy? - Insider Monkey
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Gateway Investment Advisers LLC - MarketBeat
Flywheel Private Wealth LLC Acquires New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Argent Capital Management LLC - MarketBeat
Alzheimers Drugs Market Projected To Reach USD 12.26 Bn by - GlobeNewswire
Amgen Reveals Ocrelizumab Biosimilar Ambitions - News & Insights
Wolff Wiese Magana LLC Purchases 1,644 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Avity Investment Management Inc. Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Assenagon Asset Management S.A. Cuts Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):